Navigation Links
EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
Date:12/4/2007

hown to inhibit mitotic spindle formation, prevent chromosome segregation in the M-phase (mitosis) of the cell cycle, and induce apoptosis.

Carolyn F. Sidor, M.D., M.B.A., EntreMed Vice President and Chief Medical Officer, commented on the study, "Pancreatic cancer patients continue to need more effective and better tolerated treatment options. MKC-1 has shown good activity in preclinical testing against pancreatic tumors, supporting its use in this patient population. Positive results from this clinical trial will provide the basis for designing future randomized Phase 2 studies. With this clinical trial initiation, we are now evaluating MKC-1 as a single agent or in combination in patients with pancreatic cancer, metastatic breast cancer, non- small cell lung cancer (NSCLC), and leukemia."

About Pancreatic Cancer

Pancreatic cancer is the abnormal cell growth in the tissue of the pancreas. The pancreas is an organ about six inches in length which is located behind the stomach, next to the small intestine. The pancreas produces enzymes that aide in the digestion and absorption of food. Unless pancreatic cancer is detected early, it is difficult to control. At the present time, there is no effective screening for pancreatic cancer and, because the pancreas is hidden by other organs, it is difficult to diagnosis. Pancreatic cancer is the fourth leading cause of cancer death in the United States. The American Cancer Society estimates that approximately 37,000 Americans will be diagnosed with cancer of the pancreas in 2007, resulting in approximately 33,000 deaths.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubul
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
6. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
7. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
8. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Arbor Pharmaceuticals, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:9/30/2014)... and radiotherapy at the same time could stop them ... published in Cancer Research * today (Wednesday). ... Manchester and funded by MedImmune, the global biologics research ... found that combining the two treatments helped the immune ... killed by the initial radiotherapy in mice with breast, ...
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... Randy Dotinga HealthDay Reporter ... unemployment rates climb, women tend to put the brakes on ... out to be a permanent choice, new research suggests. ... not to have a child during tough economic times. But, ... women will remain childless into their 40s and beyond. ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, Sept. ... are overweight or obese when diagnosed appear to face ... cancer, new research suggests. , , The finding didn,t ... the potential for developing other cancers associated with obesity. ... reported being overweight or obese prior to diagnosis had ...
(Date:9/30/2014)... [Brown University] Autism is no stranger to the ... African nation is access to clinical services, including reliable ... measure, for example, validated for use in Swahili, a ... study, however, researchers at Brown University and the University ... that they implemented at two sites in the country ...
Breaking Medicine News(10 mins):Health News:Immunotherapy could stop resistance to radiotherapy 2Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4
... CHICAGO, Aug. 21 Illinois U.S. Senate candidate Cheryle Jackson ... achieve the dual goals of containing costs and expanding access to ... , Jackson said that health care cooperatives are not ... national public plan that competes with the private insurance industry because ...
... ... Attract, Retain and Serve Health Insurance Consumers , ... Orlando, FL (Vocus) August 21, 2009 -- As the ... is making individual consumers become more involved in the health insurance decision-making process, as ...
... Angeles, London, New Delhi, Singapore and Washington DC (August 21, ... could benefit from a lighter touch but from a ... created a touchy-feely robot that detects tougher tumour tissue in ... human. The technique also minimises tissue damage. Surgeons have ...
... Brown adipose tissue (BAT) brown fat, which is found ... lead to new ways of preventing obesity. Studies have ... obesity. Therefore, promoting BAT function could prevent or reduce obesity ... Symonds, Professor of Developmental Physiology in the School of Clincal ...
... Aug. 21 President Obama,s Council of Advisors on Science and ... reform, energy and the environment -- and the President is listening. ... little about our healthcare system that does not concern us," said ... A primary care physician, he noted that less than 20 ...
... and good rapport with physician is key, , FRIDAY, ... acid reflux is one of the most common complaints ... appear to work best to ease patients, suffering. , ... -- formally called gastroesophageal reflux disease (GERD) -- typically ...
Cached Medicine News:Health News:U.S. Senate Candidate Cheryle Jackson: 'Public Option Critical to Real Health Care Reform' 2Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 2Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 3Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 4Health News:Robot's gentle touch aids delicate cancer surgery 2Health News:Robot's gentle touch aids delicate cancer surgery 3Health News:Daylight could help control our weight 2Health News:PCAST Members Advise President on Future of Healthcare, Energy 2Health News:Right Match of Drug, Doctor Can Boost Reflux Outcomes 2Health News:Right Match of Drug, Doctor Can Boost Reflux Outcomes 3
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
... The InstaCheck® multi-drug test device ... and easily. Negative results can ... as 3 minutes; positive results ... simple, one-time urine sample application ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... onsite test! QuickScreen™ multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
Medicine Products: